[Exclusive radiotherapy in 250 cases of stage I-II cancers of the supraglottic larynx].
Two-hundred and fifty patients presenting with a stage I-II cancer of the supraglottic larynx were definitively treated with irradiation. The 5-year disease-free survival rate is 76%. Multivariate analysis reveals that the only statistically significant prognostic parameters are clinical stage (I versus II), and tumour site (epilarynx versus supraglottis).
Glínski
B
B
Service de radiothérapie, institut oncologique, Cracovie, Pologne.
Reinfuss
M
M
Walasek
T
T
Skolyszewski
J
J
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002423:Cause of Death; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016896:Treatment Outcome
Radiothérapie exclusive de 250 cancers du larynx sus-glottique stade I-II.